,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA', 'age': 46, 'title': 'Pres, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 973760, 'exercisedValue': 0, 'unexercisedValue': 21407696}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
1,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Ms. Sherry  Aulin', 'age': 39, 'title': 'Chief Financial Officer', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 3034240, 'exercisedValue': 607697, 'unexercisedValue': 1773229}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
2,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Ms. Andrea  DiFabio J.D.', 'age': 54, 'title': 'Chief Legal Officer & Corp. Sec.', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 200510, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
3,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.', 'age': 43, 'title': 'Chief Commercial Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 618068, 'exercisedValue': 0, 'unexercisedValue': 2267715}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
4,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Dr. Christopher John Kenney M.D.', 'age': 51, 'title': 'Chief Medical Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 684218, 'exercisedValue': 0, 'unexercisedValue': 1210719}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
5,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Ms. Shelley  McCloskey B.A.', 'age': 62, 'title': 'Exec. VP of HR', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
6,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Dr. Robin P. Sherrington Ph.D.', 'age': 61, 'title': 'Exec. VP of Strategy & Innovation', 'yearBorn': 1961, 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
7,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Dr. James R. Empfield Ph.D.', 'age': 61, 'title': 'Exec. VP of Drug Discovery', 'yearBorn': 1961, 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
8,3650 Gilmore Way,Suite 200,Burnaby,BC,V5G 4W8,Canada,604 484 3300,604 484 3450,https://www.xenon-pharma.com,Biotechnology,Healthcare,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.",203,"{'maxAge': 1, 'name': 'Ms. Sheila M. Grant M.B.A., M.Sc., MBA', 'title': 'Exec. VP of R&D Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,36.68,36.88,36.335,37.55,36.68,36.88,36.335,37.55,0.0,1.34336,-10.905325,337073,337073,313972,294570,294570,35.58,36.78,1000,800,2364403200,31.79,43.75,17912.145,37.7102,38.1501,0.0,0.0,USD,1836310016,0.0,59011315,64145500,2780234,2645574,1690761600,1693440000,0.0433,0.00654,0.94595003,7.62,0.0435,10.146,3.632959,1672444800,1703980800,1688083200,-164118000,-2.52,-3.38,-0.22,13911.439,-9.963,NGM,EQUITY,XENE,XENE,Xenon Pharmaceuticals Inc.,Xenon Pharmaceuticals Inc.,1415197800,America/New_York,EDT,-14400000,36.86,60.0,46.0,52.64,52.0,1.6,buy,14,539600000,8.412,-184304992,11506000,19.238,19.341,132000,1.78,0.002,-0.15591,-0.22864,-96333000,-80231752,-130766000,0.0,0.0,-1410.1061,USD,
